Investor Contact

Media & Investor Relations:
Troy Wichterman 
Chief Financial Officer
(425) 402 - 1400
twichterman@biolifesolutions.com

Transfer Agent

Broadridge Corporate Issuer Solutions, Inc. 
P.O. Box 1342
Brentwood, New York 11717
USA
(877) 830 - 4936
shareholder@broadridge.com

Investor Alerts

Register here to receive email notifications with updates about our press releases, stock price, SEC filings and more.

Press Releases

BioLife Solutions Provides Update on Customer Cell Therapy Clinical Trials and Development Programs

BOTHELL, Wash., March 14, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers, today provided an update on several customer clinical trials and development programs using cellular therapies and cellular immunotherapies in human regenerative medicine applications.  Key developments include:

Mike Rice, BioLife's President & CEO, remarked, "This is a very exciting time for BioLife as many of our valued regenerative medicine customers continue to make excellent progress with their clinical programs assessing safety and efficacy of cellular therapies targeting the leading causes of disability and death.  We anticipate increased demand for our best in class biopreservation media products as trial enrollments are expanded in later phases and once commercial manufacturing commences after regulatory approvals are obtained by our customers.  We have the manufacturing capacity and expertise to continue to deliver high quality products and excellent customer support."

About the T Cell Immunotherapy Market:

The Roots Analysis Private Ltd November 2015 market research report estimates that the T Cell Immunotherapy market T-cell therapy market will be worth USD 30 billion by 2030. BioLife serves this market by providing best in class biopreservation media products and the biologistex™ cloud based cold chain logistics solutions to improve stability, yield, and distribution practices for time and temperature sensitive biologic materials.

About BioLife Solutions:

Our proprietary HypoThermosol® and CryoStor® biopreservation media products are critical enabling reagents used in the biobanking, drug discovery, and regenerative medicine markets. Our products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death.  These products provide commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs.  Our related biologistex cloud hosted biologistics cold chain management app for evo™ Smart Shippers offers enhanced track, trace, and notification services for shipments of time and temperature sensitive biologic materials. We also perform contract aseptic media formulation, fill, and finish services. For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

This press release contains forward-looking statements, including, but not limited to, statements concerning potential growth, business opportunities and the potential utility of and market for its products and services. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding market adoption of products; uncertainty regarding the performance of customers' clinical trials; market volatility; competition; litigation; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Media & Investor Relations
Roderick de Greef
Interim Chief Financial Officer
(425) 402-1400
rdegreef@biolifesolutions.com

 

SOURCE BioLife Solutions, Inc.